Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMC520D)

Drug Name

Cycloguanil Drug Info

Synonyms

Cycloguanil; Cycloguanyl; Cycloguanilum; 516-21-2; Chlorcycloguanil; Chlorguanide triazine; UNII-26RM326WVN; BN2410; WR 5473; BN-24-10; CHEMBL747; BRN 0229760; 1-(4-chlorophenyl)-6,6-dimethyl-1,6-dihydro-1,3,5-triazine-2,4-diamine; 26RM326WVN; QMNFFXRFOJIOKZ-UHFFFAOYSA-N; 1-(p-Chlorophenyl)-4,6-diamino-2,2-dimethyl-1,2-dihydro-s-triazine; 1-(4-chlorophenyl)-6,6-dimethyl-1,3,5-triazine-2,4-diamine; 1-p-Chlorophenyl-1,2-dihydro-2,2-dimethyl-4,6-diamino-s-triazine

Indication

Disease Entry	ICD 11	Status	REF
Malaria	1F40-1F45	Investigative	[1]

Cross-matching ID

PubChem CID: 9049
ChEBI ID: CHEBI:135029
CAS Number: CAS 516-21-2
TTD Drug ID: DMC520D

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Polypeptide deformylase (PDF)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Proguanil	DMBL79I	Malaria	1F40-1F45	Approved	[2]
Meprobamate	DMHM93Y	Anxiety		Approved	[3]
Pralatrexate	DMAO80I	Breast cancer	2C60-2C65	Approved	[4]
Ustekinumab	DMHTYK3	Plaque psoriasis	EA90.0	Approved	[5]
Trimetrexate	DMDEA85	Toxoplasmosis	1F57	Approved	[6]
MCB-3837	DM0R4Z5	Malaria	1F40-1F45	Approved	[3]
Chlorproguanil	DM1IFGT	Malaria	1F40-1F45	Approved	[3]
LY333531	DMGMC8H	Solid tumour/cancer	2A00-2F9Z	Phase 2	[7]
Metoprine	DM5GQD7	Advanced cancer	2A00-2F9Z	Phase 2	[8]
Aminopterin	DMQ9RBV	leukaemia	2A60-2B33	Withdrawn from market	[9]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Polypeptide deformylase (PDF)	TT9SL3Q	DEFM_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Opportunities and challenges in antiparasitic drug discovery. Nat Rev Drug Discov. 2005 Sep;4(9):727-40.
2	Transformation with human dihydrofolate reductase renders malaria parasites insensitive to WR99210 but does not affect the intrinsic activity of proguanil. Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10931-6.
3	The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71.
4	Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
5	Novel Saccharomyces cerevisiae screen identifies WR99210 analogues that inhibit Mycobacterium tuberculosis dihydrofolate reductase. Antimicrob Agents Chemother. 2002 Nov;46(11):3362-9.
6	Expression and characterization of recombinant human-derived Pneumocystis carinii dihydrofolate reductase. Antimicrob Agents Chemother. 2000 Nov;44(11):3092-6.
7	Three-dimensional structure of M. tuberculosis dihydrofolate reductase reveals opportunities for the design of novel tuberculosis drugs. J Mol Biol. 2000 Jan 14;295(2):307-23.
8	Mutant Gly482 and Thr482 ABCG2 mediate high-level resistance to lipophilic antifolates. Cancer Chemother Pharmacol. 2006 Dec;58(6):826-34.
9	Loss of folylpoly-gamma-glutamate synthetase activity is a dominant mechanism of resistance to polyglutamylation-dependent novel antifolates in multiple human leukemia sublines. Int J Cancer. 2003 Feb 20;103(5):587-99.